How Medication-Assisted Treatment Eases Withdrawal Symptoms

The intense physical discomfort, psychological distress, and overwhelming cravings that characterize substance withdrawal create powerful barriers to recovery. For decades, people attempting to quit opioids, alcohol, or other substances faced a stark choice: endure severe withdrawal symptoms without relief, or return to substance use to make the suffering stop. Medication-Assisted Treatment (MAT)—now increasingly called Medications for Opioid Use Disorder (MOUD) or Medications for Addiction Treatment—has transformed this landscape, providing FDA-approved medications that dramatically reduce withdrawal symptoms while supporting long-term recovery.

Understanding how MAT works, which medications treat which substances, and why this evidence-based approach saves lives can help you make informed decisions about the safest, most effective path to recovery.

What Is Medication-Assisted Treatment?

Medication-Assisted Treatment combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. The approach recognizes addiction as a chronic medical condition affecting brain chemistry—not a moral failing or simple matter of willpower—and treats it accordingly with medications that normalize brain function disrupted by substance dependence.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), MAT has been shown to:

• Improve patient survival rates
• Increase retention in treatment programs
• Decrease illicit opioid use and criminal activity
• Improve employment outcomes
• Reduce risk of infectious disease transmission (HIV, hepatitis C)
• Improve birth outcomes among pregnant women with substance use disorders

The term “Medication-Assisted Treatment” implies medications merely “assist” recovery, when in fact they represent evidence-based medical treatment for a medical condition. Increasingly, the addiction medicine community uses terms like “Medications for Opioid Use Disorder (MOUD)” or “Medications for Addiction Treatment” to accurately reflect that these medications ARE treatment, not just aids to treatment.

How MAT Works: The Science Behind the Medications

To understand how MAT medications ease withdrawal, you need to understand what happens in your brain during chronic substance use and withdrawal.

The Neurobiology of Addiction and Withdrawal

Substances like opioids, alcohol, and others affect neurotransmitter systems in the brain—particularly dopamine (reward), GABA (inhibition), and opioid receptors (pain and pleasure). Chronic use causes neuroadaptation: your brain adjusts its chemistry to accommodate constant presence of the substance.

For opioid dependence, repeated opioid use causes:

• Tolerance: Opioid receptors become less sensitive, requiring higher doses for the same effect
• Physical dependence: Brain function becomes reliant on external opioids to maintain normal operation
• Altered reward circuitry: Natural rewards no longer register as pleasurable

When opioid use stops, withdrawal occurs because your brain lacks the external opioids it has come to depend on while its own natural opioid production remains suppressed. This creates the constellation of withdrawal symptoms: severe muscle aches, bone pain, restlessness, insomnia, diarrhea, vomiting, cold flashes with goosebumps, and intense cravings.

For alcohol dependence, chronic use enhances GABA (inhibitory) activity and suppresses glutamate (excitatory) activity. When alcohol stops, you’re left with too little inhibition and too much excitation—creating dangerous neurological hyperexcitability that causes tremors, anxiety, seizures, and potentially delirium tremens.

How MAT Medications Work

MAT medications work by:

Reducing or eliminating withdrawal symptoms: By acting on the same brain receptors affected by the substance of abuse, MAT medications prevent the severe neurochemical imbalance that causes withdrawal symptoms.

Reducing cravings: By maintaining stable receptor activation, MAT medications reduce the intense drug-seeking behavior driven by cravings.

Normalizing brain chemistry: Rather than producing euphoria, MAT medications taken as prescribed normalize brain function, allowing you to engage in recovery activities, maintain employment, and rebuild your life.

Reducing overdose risk: For opioid medications specifically, maintaining tolerance through MAT reduces fatal overdose risk if relapse occurs, and blocking medications prevent euphoria from other opioids.

Medications for Opioid Use Disorder (MOUD)

Three FDA-approved medications treat opioid use disorder, each with different mechanisms and applications. According to the National Institute on Drug Abuse (NIDA), these medications reduce overdose deaths by 50% compared to no treatment—yet fewer than 1 in 5 people with opioid use disorder receive these life-saving medications.

Methadone: Full Opioid Agonist

How it works: Methadone is a long-acting synthetic opioid agonist, meaning it fully activates opioid receptors just like heroin, oxycodone, or fentanyl—but with crucial differences. Methadone works slowly (taking 30-60 minutes to take effect when taken orally), lasts 24-36 hours (compared to heroin’s 4-6 hours), and produces minimal euphoria at therapeutic doses.

How it helps withdrawal: Methadone eliminates or dramatically reduces opioid withdrawal symptoms including muscle aches, nausea, vomiting, diarrhea, sweating, insomnia, restlessness, and anxiety. Patients typically feel relief within 30-45 minutes of the first dose.

Dosing: Initial doses typically range from 10-30mg, carefully titrated based on withdrawal symptom severity. Most patients stabilize on maintenance doses of 60-120mg daily, though some require higher doses, particularly those with fentanyl dependence. Research shows that doses of 80-100mg daily produce better treatment retention than lower doses.

Administration: Methadone for opioid use disorder can only be dispensed through federally regulated Opioid Treatment Programs (OTPs), requiring daily or near-daily visits to the clinic. This structure provides built-in accountability but can create barriers for people with work or family obligations. Take-home doses may be earned with sustained stability.

Evidence: Decades of research demonstrate methadone’s effectiveness. It significantly improves treatment retention, reduces illicit opioid use, decreases criminal activity, reduces HIV and hepatitis C transmission, and improves employment outcomes.

Benefits:

• Eliminates withdrawal symptoms
• Dramatically reduces cravings
• Long duration allows once-daily dosing
• Blocks euphoric effects of other opioids
• Extensive research supporting effectiveness
• Can be used during pregnancy (though buprenorphine now often preferred)

Considerations:

• Requires daily clinic visits (initially)
• Can only be obtained through OTPs
• Can cause sedation, particularly at initiation
• Carries overdose risk if misused
• Drug interactions require careful medication management
• Some stigma associated with methadone treatment

Buprenorphine: Partial Opioid Agonist

How it works: Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors but not fully—producing about 30-50% of the effect of full agonists like heroin or methadone. It also has a “ceiling effect” where increasing doses beyond a certain point don’t increase effects, making overdose less likely. Buprenorphine binds very tightly to opioid receptors and blocks other opioids from attaching.

How it helps withdrawal: Buprenorphine reduces or eliminates opioid withdrawal symptoms and cravings while producing minimal euphoria. Patients report feeling “normal”—no high, but also no withdrawal discomfort. Within 30-60 minutes of sublingual administration, withdrawal symptoms begin resolving.

Formulations: Buprenorphine comes in several forms:

• Sublingual tablets/films: Placed under tongue, dissolve in 5-10 minutes
• Buprenorphine alone (Subutex): Less commonly prescribed
• Buprenorphine + naloxone (Suboxone): Most common formulation; naloxone discourages injection misuse
• Long-acting injections (Sublocade): Monthly injection providing consistent medication levels
• Implants (Probuphine): Six-month implant for stable patients

Dosing: Typical maintenance doses range from 8-24mg daily for sublingual products. Buprenorphine induction requires the patient be in moderate withdrawal before first dose to avoid precipitated withdrawal—a phenomenon where buprenorphine displaces other opioids from receptors, causing sudden intense withdrawal.

Administration: Unlike methadone, buprenorphine can be prescribed by any licensed healthcare provider with DEA registration authorizing Schedule III controlled substances. As of December 2022, the federal “X-waiver” requirement was eliminated, dramatically expanding access. Patients can take buprenorphine at home.

Evidence: Extensive research demonstrates buprenorphine’s effectiveness. Studies show it performs similarly to methadone in reducing illicit opioid use and improving treatment retention, with some studies suggesting methadone may have slight advantages for retention while buprenorphine offers greater flexibility.

Benefits:

• Reduces/eliminates withdrawal and cravings
• Lower overdose risk than full agonists (ceiling effect)
• Can be prescribed in office-based settings
• Take-home medication increases flexibility
• Blocks euphoric effects of other opioids
• Long-acting formulations ensure medication adherence
• Generally causes less sedation than methadone

Considerations:

• Must be in withdrawal before first dose (to avoid precipitated withdrawal)
• Some people find it less effective than methadone for severe dependence
• Sublingual films/tablets require proper administration technique
• Can be diverted or misused (though formulations with naloxone reduce this)
• May not fully eliminate cravings in people with very high tolerance

Naltrexone: Opioid Antagonist

How it works: Naltrexone is an opioid antagonist, meaning it blocks opioid receptors without activating them. If someone takes opioids while on naltrexone, they won’t feel euphoric effects. Naltrexone has no potential for misuse because it produces no subjective effects.

How it helps: Unlike methadone and buprenorphine, naltrexone doesn’t eliminate withdrawal symptoms—it prevents relapse after detoxification is complete. It works best for highly motivated individuals who have completed withdrawal and want additional protection against relapse.

Formulations:

• Oral tablets: Daily 50mg dose
• Extended-release injection (Vivitrol): Monthly injection

Administration: Naltrexone requires complete detoxification from all opioids before initiation (7-14 days for short-acting opioids, 10-14 days for methadone or buprenorphine). Starting naltrexone while opioids remain in the system causes severe precipitated withdrawal.

Evidence: Research shows naltrexone reduces relapse rates and overdose deaths, though effectiveness depends heavily on treatment retention. Extended-release injection improves adherence compared to daily pills. Studies show reduced effectiveness compared to methadone or buprenorphine for treatment retention.

Benefits:

• No potential for misuse or diversion
• Blocks euphoric effects if relapse occurs
• Non-sedating
• Extended-release form ensures adherence
• Also FDA-approved for alcohol use disorder

Considerations:

• Requires complete detoxification first (often the hardest part)
• No relief from cravings or withdrawal
• If someone relapses and uses opioids, they have no tolerance, creating overdose risk
• Less evidence for effectiveness compared to agonist therapies
• Lower treatment retention rates than methadone/buprenorphine

Comparing Opioid Medications: Which Is Best?

Research comparing these medications shows:

Retention in treatment: Methadone and buprenorphine show similar retention rates, both substantially better than naltrexone

Reduction in illicit opioid use: Methadone and buprenorphine both highly effective; some studies suggest methadone slight edge for severe dependence

Overdose prevention: People taking methadone or buprenorphine are 50% less likely to die of overdose compared to no treatment. Both dramatically outperform naltrexone for overdose prevention because they maintain tolerance.

Accessibility: Buprenorphine most accessible (any prescriber, take-home medication); methadone requires OTP visits; naltrexone accessible but requires completing detoxification first

Patient preference: Research indicates that patient preference is one of the most important factors. The best medication is often the one someone is willing to take. All three are evidence-based options; choice depends on individual circumstances, preferences, and clinical considerations.

Medications for Alcohol Withdrawal and Use Disorder

Alcohol withdrawal requires different medications because alcohol affects different neurotransmitter systems than opioids.

Benzodiazepines for Acute Alcohol Withdrawal

How they work: Benzodiazepines enhance GABA activity—essentially substituting for alcohol’s effects on GABA receptors while allowing gradual neurological readjustment. This prevents the dangerous neurological hyperexcitability that causes seizures and delirium tremens.

Common medications:

• Lorazepam (Ativan): Intermediate-acting; preferred for patients with liver disease
• Diazepam (Valium): Long-acting; excellent for seizure prevention
• Chlordiazepoxide (Librium): Long-acting; often used for less severe withdrawal

How they help: Benzodiazepines dramatically reduce withdrawal severity, prevent seizures, prevent delirium tremens, reduce cardiovascular stress, and improve comfort during the acute withdrawal phase.

Dosing: Guided by Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised (CIWA-Ar). Doses adjusted based on withdrawal severity—mild withdrawal may require minimal medication, while severe withdrawal may require substantial doses administered frequently.

Timeline: Typically tapered over 3-7 days as acute alcohol withdrawal symptoms resolve.

Medications for Long-Term Alcohol Use Disorder

After acute withdrawal, three FDA-approved medications support abstinence:

Naltrexone: Blocks opioid receptors involved in alcohol’s rewarding effects. Reduces cravings, reduces heavy drinking days, and supports abstinence. Available as daily oral medication or monthly injection (Vivitrol).

Acamprosate (Campral): Modulates glutamate and GABA systems disrupted by chronic alcohol use. Reduces cravings, improves abstinence rates, and particularly effective for people committed to complete abstinence. Requires three times daily dosing.

Disulfiram (Antabuse): Creates extremely unpleasant reaction (nausea, vomiting, headache, rapid heart rate) if alcohol is consumed. Works through deterrence rather than reducing cravings. Most effective for highly motivated individuals with supervision.

Medications for Stimulant Withdrawal

Currently, no FDA-approved medications specifically treat cocaine or methamphetamine withdrawal. However, various medications address specific symptoms:

Sleep medications: Manage severe insomnia disrupting recovery Antidepressants: Address withdrawal-related depression Anti-anxiety medications: Manage anxiety symptoms Modafinil: Under investigation for reducing cocaine use

Research continues investigating promising medications for stimulant use disorders, but currently treatment relies primarily on behavioral therapies combined with symptomatic medication management.

Medications for Cannabis Withdrawal

No FDA-approved medications treat marijuana withdrawal specifically. Treatment focuses on symptom management with sleep aids, anti-anxiety medications if needed, and behavioral interventions.

The MAT Process: What to Expect

Understanding the MAT process helps reduce anxiety about starting medication.

Initial Assessment

Comprehensive evaluation includes substance use history, medical conditions, mental health status, previous treatment attempts, current medications, social circumstances, and treatment goals.

Induction (For Opioid Medications)

Methadone induction: Start low (10-30mg), observe response, adjust dose based on symptom control and side effects. Doses increased gradually over days to weeks until stabilizing dose reached.

Buprenorphine induction: Must be in moderate withdrawal before first dose (to avoid precipitated withdrawal). First dose typically 2-4mg, observe 30-60 minutes, give additional doses if needed. Most patients stabilize on 8-24mg daily. Induction takes 1-3 days.

Naltrexone initiation: Requires 7-14 days opioid-free. Naloxone challenge dose may be given to confirm no opioids remaining in system (if withdrawal occurs, opioids still present).

Stabilization

Dose adjustment period where medication is optimized to eliminate withdrawal/cravings without causing excessive sedation or side effects. May take days to weeks to find optimal dose.

Maintenance

Long-term medication continuation. Research consistently shows that longer treatment duration improves outcomes. Many people benefit from continuing medication indefinitely—just as people with diabetes take insulin long-term, people with opioid use disorder may benefit from long-term MOUD.

Tapering (If Appropriate)

Some people eventually taper off medication, though this carries relapse risk. Tapering should be very gradual, closely monitored, and only undertaken when the person is stable with strong recovery support systems. Many experts recommend indefinite maintenance rather than tapering.

Combining MAT with Behavioral Therapies

Medication alone is not enough—MAT works best combined with counseling and behavioral therapies. This comprehensive approach addresses both the neurochemical aspects of addiction (through medication) and psychological/behavioral aspects (through therapy).

Cognitive Behavioral Therapy (CBT): Identifies and changes thought patterns and behaviors contributing to substance use

Dialectical Behavior Therapy (DBT): Teaches emotion regulation, distress tolerance, mindfulness

Contingency Management: Provides rewards for abstinence

Motivational Enhancement Therapy: Builds motivation for sustained recovery

Group therapy: Peer support and shared learning

Individual counseling: Addresses personal factors underlying substance use

Dual diagnosis treatment: Integrated care for concurrent mental health conditions

The combination of medication and therapy produces better outcomes than either alone.

Common Myths and Misconceptions About MAT

Myth: “MAT just substitutes one addiction for another”

Reality: This misunderstands addiction. Methadone and buprenorphine, taken as prescribed, normalize brain function without producing euphoria. They allow people to work, maintain relationships, and engage in recovery—none of which is possible during active addiction. The goal is stability and functionality, not abstinence from all substances at all costs.

Myth: “Real recovery means being completely medication-free”

Reality: We don’t criticize people with diabetes for taking insulin or people with depression for taking antidepressants. Addiction is a chronic medical condition affecting brain chemistry. Medications that normalize brain function enable recovery, they don’t prevent it.

Myth: “MAT makes withdrawal worse later”

Reality: This confuses withdrawal from illicit opioids with medical tapering. Properly supervised tapering from MAT medications (if undertaken) involves gradual dose reduction over months, making withdrawal manageable. But more importantly, indefinite maintenance is often appropriate and beneficial—just as many chronic conditions require long-term medication.

Myth: “MAT doesn’t work for everyone, so it’s not worth trying”

Reality: No treatment works for everyone, but MAT reduces overdose deaths by 50% and significantly improves treatment retention and quality of life for the majority who try it. The alternatives—unsupported withdrawal or continued illicit use—carry far worse outcomes.

Myth: “You can’t get MAT if you’re pregnant”

Reality: MOUD is safe and recommended during pregnancy. Untreated opioid use disorder during pregnancy carries substantial risks for both mother and baby. Both methadone and buprenorphine are safe for use during pregnancy, with buprenorphine increasingly preferred.

The Colorado Advantage: MAT at Healing Pines Recovery

Healing Pines Recovery integrates medication-assisted treatment into comprehensive substance use treatment in Elizabeth, Colorado. The program recognizes that addressing the neurochemical aspects of addiction through appropriate medication is essential for many people’s recovery success.

For opioid use disorder, the program provides buprenorphine-based treatment integrated with residential programming. This combination allows men to stabilize on medication while receiving intensive therapeutic intervention addressing underlying factors driving opioid use.

For alcohol use disorder, medical detoxification includes appropriate benzodiazepine protocols preventing dangerous complications, followed by integration of FDA-approved medications (naltrexone, acamprosate) supporting long-term abstinence.

The men-focused program addresses gender-specific aspects of substance use and recovery. The evidence-based approach combines medication when appropriate with proven therapies, dual diagnosis care, and holistic practices including outdoor therapy in Colorado’s mountains.

The comprehensive approach recognizes that MAT works best as part of total treatment addressing all aspects of recovery—medical, psychological, social, and spiritual.

Don’t let fears about withdrawal prevent you from seeking recovery. Contact Healing Pines Recovery at 720-575-2621 to discuss how medication-assisted treatment can ease withdrawal symptoms and support your recovery journey in Colorado’s healing mountain environment.

Frequently Asked Questions

What is medication-assisted treatment?

MAT combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. For opioid use disorder, three medications are available: methadone, buprenorphine, and naltrexone. These medications normalize brain chemistry disrupted by chronic opioid use, dramatically reducing withdrawal symptoms and cravings. According to NIDA, people taking methadone or buprenorphine are 50% less likely to die of overdose compared to no treatment. MAT is considered the gold standard for opioid use disorder treatment.

Does MAT just substitute one drug for another?

No. This common misconception misunderstands how MAT medications work. When taken as prescribed, methadone and buprenorphine normalize brain function without producing euphoria. They allow you to work, maintain relationships, and engage in recovery activities—none of which is possible during active addiction. According to SAMHSA, MAT patients are more likely to maintain employment, avoid criminal behavior, reduce HIV risk, and engage in counseling. The goal is stability and functionality, not complete abstinence from all medications.

How long do you need to stay on MAT medications?

Research shows longer treatment duration improves outcomes. Many people benefit from continuing medication indefinitely—similar to how people with diabetes take insulin long-term. Some people eventually taper off after years of stability, but this carries relapse risk. The decision should be made collaboratively with your treatment team based on your individual circumstances. There’s no “right” timeline—what matters is what supports your sustained recovery.

Will MAT medications make me feel high?

No, when taken as prescribed. Methadone and buprenorphine at therapeutic doses produce minimal euphoria. Patients typically report feeling “normal”—no withdrawal symptoms, reduced cravings, but no high. This is the point: normalizing brain function allows you to engage in life and recovery work. Naltrexone produces no subjective effects at all because it blocks rather than activates opioid receptors.

Can I get MAT if I’m pregnant?

Yes, MAT is safe and recommended during pregnancy. Untreated opioid use disorder during pregnancy carries substantial risks including maternal overdose death, inadequate prenatal care, fetal growth restriction, placental abruption, and neonatal complications. Both methadone and buprenorphine are safe for pregnancy, with buprenorphine increasingly preferred. According to medical guidelines, pregnant women should continue or initiate MOUD rather than attempting detoxification.

Does insurance cover MAT? Yes, most insurance plans cover MAT. The Mental Health Parity and Addiction Equity Act requires substance use disorder treatment, including medications, be covered similarly to other medical conditions. This means MAT should be covered with copays/deductibles comparable to other prescription medications. Healing Pines Recovery accepts most major insurance and can verify your coverage. The admissions team helps navigate insurance to ensure access to appropriate medication-assisted treatment.

What’s the difference between methadone and buprenorphine?

Methadone is a full opioid agonist administered daily through Opioid Treatment Programs (OTPs), while buprenorphine is a partial agonist that can be prescribed by any licensed provider and taken at home. Both effectively reduce withdrawal and cravings. Methadone may provide better treatment retention for severe dependence, while buprenorphine offers greater flexibility and accessibility. Neither is universally “better”—the choice depends on individual factors, access, and preference.

Can I work while on MAT?

Yes, MAT enables you to work. Unlike active addiction or untreated withdrawal, MAT medications normalize brain function, allowing you to maintain employment. Research shows MAT patients have significantly improved employment outcomes compared to those not receiving medication treatment. The medications don’t cause impairment when taken as prescribed—they eliminate the chaos of addiction and withdrawal that prevents normal functioning.

What if MAT doesn’t work for me?

If one medication doesn’t work well, others might. Some people respond better to methadone than buprenorphine or vice versa. Dose optimization is crucial—too low a dose won’t adequately control symptoms, while too high causes side effects. The medication should be combined with behavioral therapies addressing psychological aspects of addiction. If you’ve tried MAT unsuccessfully, discuss with your treatment team whether dose adjustment, medication switch, or additional therapeutic interventions might help.

Is MAT available at Healing Pines Recovery?

Yes, Healing Pines Recovery integrates appropriate medications into comprehensive treatment. For opioid use disorder, buprenorphine-based treatment is available integrated with residential programming. For alcohol use disorder, medical detoxification includes benzodiazepine protocols, with FDA-approved medications supporting long-term abstinence. The approach combines medication when clinically indicated with evidence-based therapies, creating comprehensive treatment addressing all aspects of recovery. Contact 720-575-2621 to discuss medication options.